In April, 2025, Demis Hassabis, the Nobel Prize-winning CEO of Google DeepMind, appeared on the US television show 60 Minutes and suggested that all diseases could be curable with the help of ...

Investing.com -- Dyne Therapeutics, Inc. (NASDAQ: DYN) reported a second quarter loss that slightly missed analyst expectations as the clinical-stage biotech company continues to advance its ...

Investing.com -- PTC Therapeutics (NASDAQ: PTCT) stock rose 9% after the company announced that the U.S. Food and Drug Administration (FDA) has approved its drug SEPHIENCE (sepiapterin) for the ...

Research has suggested that about 40% of dementia cases could be prevented or delayed by addressing 14 modifiable risk factors — alcohol abuse, smoking, diabetes, obesity, high ...

The U.S. Food and Drug Administration (FDA) announced on Friday, after market close, that it is investigating the death of an ...

Over the past decade, health insurance companies have increasingly embraced the use of artificial intelligence algorithms – ...

We recently compiled a list of 10 Best Mid Cap Stocks to Buy According to Billionaires. Mesoblast Limited stands tenth on our ...

The Centers for Medicare and Medicaid Services (CMS) is looking to reduce the volume of "low value" services furnished to Original ...

Durvalumab's breakthrough therapy designation offers hope for improved outcomes in early-stage gastric and GEJ cancers, potentially transforming treatment strategies.

Investing.com -- Maia Biotechnology Inc (NYSE: MAIA) stock surged 11.2% in pre-market trading after the company announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track ...

With the introduction of genAI tool Elsa at the FDA in June, the technology is playing a greater role in the medical device review process.